Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience.
adjuvant therapy
ovarian cancer
ovarian carcinosarcoma
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
22 Nov 2019
22 Nov 2019
Historique:
received:
23
10
2019
revised:
08
11
2019
accepted:
19
11
2019
entrez:
27
11
2019
pubmed:
27
11
2019
medline:
27
11
2019
Statut:
epublish
Résumé
Carcinosarcoma of the ovary (CSO) is a rare and aggressive variant of ovarian cancer. Due to the rare nature of the disease there is insufficient evidence to make recommendations regarding standard management and overall prognosis. An Institutional Review Board-approved study identified all our patients with CSO between January 2011 and May 2018. Demographic and outcome measures were abstracted from the medical records and tumor board files. Cox proportional hazard models, log rank tests, and comparisons of means were used to calculate significance ( 27 women with CSO were identified. The median age at diagnosis was 65 years (range 48-91). Five women (18%) presented with early stage disease (Stage I or II) and 22 patients (82%) presented with late stage III or IV disease. Twenty patients (74%) received intravenous platinum-based combination chemotherapy. Seven patients did not receive chemotherapy during their treatment course. The median overall survival was 23 months (range 2-68 months). Overall survival was not significantly worsened by the stage of disease at diagnosis. There was no difference in survival based on the age at diagnosis, tobacco status or ethnicity ( This is one of the largest single institution experiences with CSO. The majority of our patients presented with advanced stage disease and received adjuvant platinum-based chemotherapy after cytoreductive surgery. The median overall survival of 23 months was not affected by the stage of the disease. The optimal management of this rare disease needs further study with collaborative, prospective multi-institutional trials.
Sections du résumé
BACKGROUND
BACKGROUND
Carcinosarcoma of the ovary (CSO) is a rare and aggressive variant of ovarian cancer. Due to the rare nature of the disease there is insufficient evidence to make recommendations regarding standard management and overall prognosis.
METHODS
METHODS
An Institutional Review Board-approved study identified all our patients with CSO between January 2011 and May 2018. Demographic and outcome measures were abstracted from the medical records and tumor board files. Cox proportional hazard models, log rank tests, and comparisons of means were used to calculate significance (
RESULTS
RESULTS
27 women with CSO were identified. The median age at diagnosis was 65 years (range 48-91). Five women (18%) presented with early stage disease (Stage I or II) and 22 patients (82%) presented with late stage III or IV disease. Twenty patients (74%) received intravenous platinum-based combination chemotherapy. Seven patients did not receive chemotherapy during their treatment course. The median overall survival was 23 months (range 2-68 months). Overall survival was not significantly worsened by the stage of disease at diagnosis. There was no difference in survival based on the age at diagnosis, tobacco status or ethnicity (
CONCLUSION
CONCLUSIONS
This is one of the largest single institution experiences with CSO. The majority of our patients presented with advanced stage disease and received adjuvant platinum-based chemotherapy after cytoreductive surgery. The median overall survival of 23 months was not affected by the stage of the disease. The optimal management of this rare disease needs further study with collaborative, prospective multi-institutional trials.
Identifiants
pubmed: 31766630
pii: diagnostics9040200
doi: 10.3390/diagnostics9040200
pmc: PMC6963805
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Gynecol Oncol. 1994 Apr;53(1):24-6
pubmed: 8175017
Gynecol Oncol. 2007 Jun;105(3):657-61
pubmed: 17395252
Gynecol Oncol. 2002 Jun;85(3):459-63
pubmed: 12051874
Gynecol Oncol. 2006 Jan;100(1):128-32
pubmed: 16213011
Gynecol Oncol. 2004 May;93(2):336-9
pubmed: 15099942
Gynecol Oncol. 2016 Jul;142(1):38-43
pubmed: 27107722
Oncology. 2011;80(1-2):102-6
pubmed: 21677454
Gynecol Oncol. 2008 Jan;108(1):136-40
pubmed: 17936342
Cancer. 2004 May 15;100(10):2148-53
pubmed: 15139057
Gynecol Oncol. 2004 May;93(2):506-12
pubmed: 15099970
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
Gynecol Oncol. 2013 Oct;131(1):46-51
pubmed: 23906658
PLoS One. 2017 Jan 26;12(1):e0170879
pubmed: 28125702
Gynecol Oncol. 2011 Jun 1;121(3):477-81
pubmed: 21420726
Obstet Gynecol. 1992 Oct;80(4):660-4
pubmed: 1328975